A Phase 1/2 Study of the SpectraCure P18 System and Verteporfin in People With Early-Stage Prostate Cancer

Full Title

Open-label Clinical Phase 1/2 Study to Assess the Safety and Efficacy of the SpectraCure P18 System and Verteporfin for Injection for the Treatment of Primary Localized Prostate Cancer

Purpose

Doctors are assessing a new photodynamic therapy (PDT) for prostate cancer that has not spread beyond the prostate. This treatment is performed in an operating room while you are under general anesthesia.

First you will receive an injection of a drug called verteporfin. Verteforfin reacts in the presence of bright light to kill cancer cells. After verteporfin reaches the prostate gland, laser light is applied inside the prostate using the SpectraCure P18 PDT system. The laser light activates the drug to kill cancer cells.

Who Can Join

To join this study, there are a few conditions. You must:

• Have prostate cancer that is only in the prostate gland and has not yet been treated.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Jonathan Fainberg’s office at 646-422-4894.